EFFICIENCY OF RONCOLEUKIN® IN TREATMENT OF CHRONIC RECURRENT INFECTIONS

Medicinskaâ Immunologiâ

O. Yu. Leplina¹  E. R. Chernykh¹  A. A. Ostanin¹  M. A. Tikhonova¹  N. M. Starostina¹  O. I. Zheltova¹ 

[1] НИИ клинической иммунологии СО РАМН, г. Новосибирск;

关键词: cytokine balance;    regulatory t-cells;    cytokine therapy;    il-2;    recurrent infections;   

DOI  :  10.15789/1563-0625-2011-2-3-227-236

来源: DOAJ

【 摘 要 】

Аbstract.  Сlinical  and  immunocorrective  efficiency  of  Roncoleukin®  (IL-2)  monotherapy  applied  as subcutaneous injections versus inhalatory mode of treatment, was studied in patients with chronic recurrent infections. It was shown that administration of Roncoleukin® at a total dose of 1.5 mg was accompanied by increased activity of Th1 lymphocytes and reduced in vitro production of IL-10, and does not exert any adverse immunotropic effects associated with Treg expansion. In general, the positive clinical effect was registered in 65% (26/40) of the patients, and its duration ranged between 3 and 7 months (a mean of 4.4±0.2 months). Clinical  efficiency  of  Roncoleukin®  inhalations  proved  to  be  not  inferior  to  conventional  Roncoleukin® immunotherapy performed by subcutaneous injections (resp., 70 and 60% of positive responses), and allows a more significant prolongation of event-free remission. (Med. Immunol., 2011, vol. 13, N 2-3, pp 227-236)

【 授权许可】

Unknown